Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06610799
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-18
Brief Title:
Study of IBI363 in Patients With Advanced First-line Gastric Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase Ib Study to Evaluate the Safety Tolerability and Efficacy of IBI363 in Combination With Oxaliplatin and Capecitabine XELOX in First-line Treatment of Unresectable Advanced or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 1b study designed to evaluate the safety tolerability and efficacy of IBI363 in combination with oxaliplatin and capecitabine XELOX in first-line treatment of unresectable advanced or metastatic gastric and gastroesophageal junction adenocarcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None